These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37194518)

  • 1. [Therapeutic Strategies for Neuromyelitis Optica].
    Nakashima I
    Brain Nerve; 2023 May; 75(5):493-497. PubMed ID: 37194518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Events in NMOSD Therapy.
    Giglhuber K; Berthele A
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of neuromyelitis optica: an evidence based review.
    Sato D; Callegaro D; Lana-Peixoto MA; Fujihara K;
    Arq Neuropsiquiatr; 2012 Jan; 70(1):59-66. PubMed ID: 22218475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
    Miyamoto K; Kusunoki S
    Ther Apher Dial; 2009 Dec; 13(6):505-8. PubMed ID: 19954473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
    Holmøy T; Høglund RA; Illes Z; Myhr KM; Torkildsen Ø
    J Neurol; 2021 Dec; 268(12):4522-4536. PubMed ID: 33011853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and treatment of neuromyelitis optica].
    Nielsen HH; Ravnborg M; Illes Z
    Ugeskr Laeger; 2014 Jun; 176(26):V02130104. PubMed ID: 25294570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of neuromyelitis optica].
    Nomura K
    Nihon Rinsho; 2013 May; 71(5):829-38. PubMed ID: 23777090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and clinical management of patients with neuromyelitis optica and anti-aquaporin 4 antibody].
    Ochi H
    Brain Nerve; 2010 Sep; 62(9):945-52. PubMed ID: 20844305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neuromyelitis optica].
    Nakashima I
    Rinsho Shinkeigaku; 2012; 52(11):1231-3. PubMed ID: 23196573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
    Kim SM; Park J; Kim SH; Park SY; Kim JY; Sung JJ; Park KS; Lee KW
    PLoS One; 2013; 8(12):e82325. PubMed ID: 24358171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
    Nakashima I; Nakahara J; Yasunaga H; Yamashita M; Nishijima N; Satomura A; Nio M; Fujihara K
    Mult Scler Relat Disord; 2024 Apr; 84():105502. PubMed ID: 38401202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.
    Miao J; Aboagye DE; Chulpayev B; Liu L; Ishkanian G; Kolanuvada B; Alaie D; Petrillo RL
    Am J Case Rep; 2018 Jan; 19():41-46. PubMed ID: 29321467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
    Elsone L; Kitley J; Luppe S; Lythgoe D; Mutch K; Jacob S; Brown R; Moss K; McNeillis B; Goh YY; Leite MI; Robertson N; Palace J; Jacob A
    Mult Scler; 2014 Oct; 20(11):1533-40. PubMed ID: 24647557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model.
    Lazzaro C; Mazzanti NA; Rossi S; Parazzini F
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1185-1200. PubMed ID: 37795872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.
    Kleiter I; Gold R
    Neurotherapeutics; 2016 Jan; 13(1):70-83. PubMed ID: 26597098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.